Subscribe to Search results

Gillian Merron accepted an invite from Lord Morris to meet with him regarding her statement in the House of Commons.

Published on:

Gillian Merron met with Lord Morris.

Published on:

Gillian Merron met with Edward O'Hara MP and Sylvia Heal MP, where the question of comparability with Ireland was raised again.

Published on:

Gillian Merron's Assistant Private Secretary asked Dr Rowena Jecock to provide options for bringing forward the review of the Skipton Fund.

Published on:

Dr Rowena Jecock and her team published a briefing paper, which advised against bringing the review of the Skipton Fund forward on the basis that the Department of Health was already over-committed on funding for 2010-2011.

Published on:

Deborah Webb authored a briefing that outlined three alternative options following Gillian Merron's request for further advice on options to bring forward a review of the Skipton Fund.

Published on:

A meeting took place between the Secretary of State, Gillian Merron, Dr Rowena Jecock and Deborah Webb. A follow-up email confirmed Gillian Merron's clear preference to bring forward a full review of the Skipton Fund.

Published on:

Advice to make the announcement by way of a written ministerial statement was given by Dr Rowena Jecock.

Published on:

A briefing was provided to the Secretary of State advising that leave to appeal should be sought.

Published on:

When the Edinburgh cohort were identified as having been infected with HTLV-3 through the use of PFC products, it was discovered that 4,000 donors had contributed to the implicated batch.

Published on:

Pool sizes for continuous thawing were between 600kg and 1,000kg, depending upon the size of freeze dryer available.

Published on:

Although the PFL produced a small number of batches from limited donor pools using plasma from a small number of plasmapheresis donors, this product still resulted in some hepatitis transmission.

Published on:

A paper published by Dr Peter Kernoff, Dr Christine Lee and others recorded that a cohort of patients followed up between April 1978 and March 1983 showed close to a 100% rate of infection after first exposure to clotting factor products, with those using NHS concentrates faring only slightly better than those using commercial concentrates.

Published on:

At a meeting of the Blood Products Advisory Committee of the Centre for Biologics Evaluations and Research, it was noted that paid donors had plasma collected from them between 40 and 60 times per year on average, and that 4 infected persons could contaminate "the entire world supply of Factor VIII" due to the large US pool sizes.

Published on:

At a meeting of the Blood Products Advisory Committee, it was noted that one infected donation could easily be represented in as many as 50 plasma pools in one year, with up to 250 million international units of Factor 8 activity potentially affected.

Published on:

Dr Terence Snape said in oral testimony that at PFL, product labels were generated and overprinted on commercially produced labels "even up to 1982".

Published on:

A list of Factor 8 labels produced between 1985-1987 contained statements as to the maximum pool size (eg "Less than 7,500 plasma donations were used in the preparation of this batch"), and some indication as to risk ("The preparation is of human origin and cannot be assumed to be free of hepatitis virus").

Published on:

Dr Robert Perry, the director of PFC, said in oral testimony that if pool sizes hadn't been increased in the early 1980s, then production in the UK wouldn't have kept up with demand and the only alternative would have been to buy more commercial product "which would have been the worst of all outcomes".

Published on:

In 1978, Factor 8 products from PFC had labels warning that: "Product may carry the risks of transmitting serum hepatitis". PFC Factor 9 labels warned that: "none of these tests are of sufficient sensitivity to eliminate the possibility of transmitting hepatitis...the risk of transmission cannot be disregarded."

Published on:

Dr Robert Perry, the director of PFC, commented in oral testimony that the leaflets accompanying Factor 8 and 9 concentrates were primarily targeted at the prescribing doctor "and, in a sense, they had a much closer working knowledge of risks of hepatitis non-A, non-B, hepatitis B and, latterly, HIV than the manufacturer of the products. So none of this information would have been a surprise to a treating doctor."

Published on: